Under the amended agreement, which is extended for an additional two years through 2015, Nordion expects to supply Mo-99 on a weekly basis to Lantheus Medical.

Mo-99 medical isotope is designed for use by physicians to diagnose and treat various diseases including cardiac and neurological conditions, and several types of cancer.

Nordion chief executive officer Steve West said the agreement provides the company with additional clarity of the multi-year demand for its Mo-99.

"Both Nordion and Lantheus continue to be important participants in the global supply chain for Mo-99 which is so critical to physicians and patients worldwide," West added.

Lantheus Medical Imaging president and chief executive officer Don Kiepert said, "This multi-year agreement with Nordion underlines our commitment to serving the global nuclear medicine community through a diversified and balanced supply chain for Mo-99."